{"success":true,"data":{"pressRelease":{"id":"161186","rtpr_id":"nBw3BP9rda-20261006","ticker":"GALD","exchange":"","all_tickers":["GALD"],"title":"30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation ","author":"Business Wire","published_at":"2026-10-06T05:00:00.191Z","article_body":"30 Years of Restylane(®): Reshaping the Aesthetics Field Through Science-Led,\nPatient-Centric Innovation\n\n\n * Galderma celebrates the 30(th) anniversary of Restylane, its pioneering range\nof hyaluronic acid (HA) injectables that established the category as the first\nto market(1 )\n\n * With three decades of innovation across technology, packaging, and treatment\nareas, Restylane continues to meet growing aesthetic needs, including emerging\nareas such as medication-driven weight loss, skin quality and menopause(1-11)\n\n * This year’s milestones include the approvals of Restylane Shaype™ in the\nEuropean Union (EU) for enhancement of the chin region, the new\nstate-of-the-art Restylane syringe in the EU, United States (U.S.), and\nCanada, and Restylane Volyme™* in the U.S. for temple hollowing, with a\ndual-layer patent-pending technique leveraging both needle and cannula(12-18)\n\n * With more than 80 clinical trials, 180 publications, around 407,000 patients\nevaluated for safety, and 77 million treatments administered worldwide,\nRestylane remains a pioneer in science-backed aesthetic innovation and\ncontinues to shape the future of HA injectables(1-3,19,20)\n\nGalderma (SIX: GALD), the pure-play dermatology category leader, celebrates 30\nyears since Restylane was launched in Europe as the first hyaluronic acid (HA)\ninjectable.(1 )With HA closest to the skin’s own, Restylane is designed to\ndeliver personalized, natural-looking outcomes that meet diverse patient needs\nacross key areas of the face, décolletage, and hands.(8,10,12,21-31) With\nthree decades of innovation across technology, packaging, and treatment areas,\nRestylane remains at the forefront of innovation, evolving from its original\nNASHA(®), technology into a comprehensive portfolio spanning three distinct\ntechnologies: NASHA HD™, NASHA(®), and OBT™.(1,8,21,22 )Together, these\ntechnologies offer solutions ranging from firmer gels that provide contouring\nand structural support, to soft, flexible formulations that smooth facial\nlines and wrinkles for a more youthful look.(8,12,21-31)\n\nThis press release features multimedia. View the full release here:\nhttps://www.businesswire.com/news/home/20261005211995/en/\n(https://www.businesswire.com/news/home/20261005211995/en/)\n\nThe Restylane portfolio has most recently achieved EU Medical Device\nRegulation certification for the products created with NASHA HD™, NASHA(®),\nand OBT™ technologies.(12,23-29) As one of the world's most rigorous medical\ndevice regulatory frameworks, the certification reinforces confidence in the\nstrong safety profile, quality standards and scientific foundation behind the\nportfolio.(32)\n                                                                                      \n  “Restylane's 30-year journey is a testament to Galderma's enduring                  \n commitment to science-led innovation in aesthetics. Supported by extensive           \n clinical experience – including more than 400,000 patients evaluated for             \n safety – and robust real-world data, Restylane has helped define aesthetics,         \n setting a high standard for safety, efficacy and natural-looking results since       \n it launched as the first HA injectable three decades ago. With market                \n penetration still relatively low, significant opportunities remain to expand         \n adoption, and as we look to the future, we will continue to build on this            \n foundation through innovation that reinforces the essential role of HA               \n injectables in the future of aesthetics.”                                            \n \n                                                                                    \n \nBALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.                                           \n \nGLOBAL HEAD OF R&D                                                                  \n \nGALDERMA                                                                            \n                                                                                      \n\n\nExpanding Restylane’s versatility to support tailored aesthetic outcomes\n\nRestylane continues to expand treatment possibilities through new\ntechnologies, indications, and devices.\n\nRestylane Shaype was recently approved\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.galderma.com%2Fnews%2Fgalderma-receives-european-union-approval-restylaner-shaypetm-first-and-only-bone-mimicking&esheet=54616526&newsitemid=20261005211995&lan=en-US&anchor=approved&index=1&md5=d123a6254beb79d5ae7c48bc4aad7fd6)\nin the EU for correction and enhancement of the chin region.(12) Powered by\nGalderma’s new NASHA HD™ technology, it is the firmest HA injectable gel\navailable among facial filler market leaders, delivering a unique\nbone-mimicking effect that enables immediate, natural-looking structural\nenhancement in the lower face.(12,21,33) Restylane Shaype is the first\nminimally invasive injectable aesthetic option to provide structure in this\nincreasingly important treatment area, which has previously largely relied on\nsurgical implants.(21)\n\nA new state-of-the-art Restylane syringe was also approved in the EU, U.S. and\nCanada earlier this year, for use with the NASHA(®) lidocaine Restylane\nproducts in multiple facial indications.(13-15 )It was designed in\ncollaboration with over 70 aesthetics practitioners to be optimized for\nergonomic functionality, ease of aspiration, and ease of operation.(34-37) It\nhas compact blister-free packaging that is 100% recyclable and reduces\nin-clinic waste by up to 30% based on volume reduction.(38,39 )A survey of\nover 300 healthcare professionals in Brazil who had personal experience using\nthe Restylane syringes found that 89% preferred the next-generation syringe\nover the standard syringe.(40) The next-generation syringe complements\nGalderma’s patented SmartClick™ syringe for Restylane Skinboosters™,\nwhich monitors each micro-dose, allowing injectors to focus on technique and\nplacement for enhanced patient safety, precision and control.(31,41)\n\nAs global demand grows for treatments that address the evolving effects on the\nskin of aging, menopause, and weight loss, Restylane Volyme received U.S.\napproval in March for the correction of temple hollowing with a dual-layer\npatent-pending technique leveraging both needle and cannula.(16-18) Temple\nvolume loss can disrupt facial balance and harmony, and contribute to a tired,\nsunken, and aged appearance, a challenge increasingly seen in people\nundergoing medication-driven weight loss and experiencing age- and\nhormone-related changes, including menopause.(6,18,42)\n                                                                                      \n  “Restylane has been a trusted part of my practice for many years, thanks            \n to the constant innovations brought to the portfolio in terms of product,            \n indications and even packaging. Today, I treat an increasingly diverse range         \n of individuals seeking personalized, natural-looking results, so having a            \n versatile portfolio that goes beyond volumizing and can provide lift, contour,       \n definition and skin quality improvements across multiple areas of the face and       \n body is invaluable. Supported by decades of science, Restylane gives me the          \n confidence to tailor treatments to each patient’s unique anatomy, goals and          \n stage of life.”                                                                      \n \n                                                                                    \n \nDR. LUDDI LUIZ OLIVEIRA                                                             \n \nPLASTIC SURGEON                                                                     \n \nBRAZIL                                                                              \n                                                                                      \n\n\nRestylane expands access to injectable aesthetics for new patient segments\n\nRestylane remains highly relevant in addressing some of today’s most\nsignificant aesthetic trends and needs including medication-driven weight\nloss, menopause and skin quality.\n\nInterim results\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.galderma.com%2Fnews%2Finterim-data-two-ongoing-investigator-initiated-trials-highlight-role-sculptra-and-restylane&esheet=54616526&newsitemid=20261005211995&lan=en-US&anchor=results&index=2&md5=ddcf2456f74da3133ba5f503761cfef1)\nfrom an investigator-initiated trial showed that combining Restylane\nSkinboosters with Sculptra(®) – the first proven regenerative\nbiostimulator( )–( )drove progressive improvements in hydration, skin\nbarrier function, and overall skin quality in menopausal women.(4,43-46 )These\nresults are reinforced by consensus guidelines concluding that Restylane\nSkinboosters can complement Sculptra in the décolletage for comprehensive\nbody rejuvenation.(47)\n\nAdditionally, Restylane also has an important role in addressing the aesthetic\nconcerns of patients experiencing facial volume loss associated with\nmedication-driven weight loss.(11) The combination of Restylane Lyft™ or\nVolyme with Sculptra has been shown to deliver visible improvements in skin\nquality and significantly enhance patient satisfaction and emotional\nwellbeing.(11)\n\nSupported by 30 years of innovation and more than 77 million treatments\nadministered worldwide, Restylane has helped define the HA injectable category\nand continues to shape the future of aesthetic medicine.(1-3) With more than\n80 clinical trials, 180 publications and around 407,000 patients evaluated for\nsafety, its legacy is built on extensive scientific evidence and clinical\nexperience.(3,19) These milestones demonstrate Galderma’s ongoing commitment\nto using its unique dermatology expertise and strong portfolio to meet the\nneeds of patients and healthcare professionals today and tomorrow.\n\n*Restylane Volyme is known as Restylane Contour™ in the U.S.\n\nAbout the Restylane portfolio\n\nRestylane HA treatments are designed differently to go beyond volumizing for\nnatural-looking results.(2,24,48) Our HA is minimally modified and our\ninnovative manufacturing process preserves its biocompatibility while creating\nindividual products designed for a specific purpose.(7,10,49) Powered by NASHA\nHD™, NASHA(®), and OBT™ technologies, Restylane offers gels with the\nhighest firmness to the highest flexibility, enabling personalized treatments\nthat deliver structural support, natural-looking results, and a healthy\nglow.(8,21,22,33) Trusted for almost three decades, our HA gels work in sync\nwith your skin for 100% natural-looking results.(2,50,51) Approved indications\nvary by market.\n\nAbout Galderma\n\nGalderma (SIX: GALD) is the pure-play dermatology category leader, present in\napproximately 90 countries. We deliver an innovative, science-based portfolio\nof premium flagship brands and services that span the full spectrum of the\nfast-growing dermatology market through Injectable Aesthetics, Dermatological\nSkincare and Therapeutic Dermatology. Since our foundation in 1981, we have\ndedicated our focus and passion to the human body’s largest organ – the\nskin – meeting individual consumer and patient needs with superior outcomes\nin partnership with healthcare professionals. Because we understand that the\nskin we are in shapes our lives, we are advancing dermatology for every skin\nstory. For more information: www.galderma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.galderma.com%2F&esheet=54616526&newsitemid=20261005211995&lan=en-US&anchor=www.galderma.com&index=3&md5=fac463f7d2fcbee7a840240376e77c30)\n.\n\nReferences\n\n\n 1. Galderma. Data on file. MA-57232 [Updated]. 77 Million treated.\n\n 2. Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of\ninjectable HA fillers for facial aesthetic treatment. E-poster presented at\nAMWC; March 27-29, 2024; Monaco.\n\n 3. Galderma. Data on file. MA-55607. Restylane(®) 27 years data publications\nanalysis.\n\n 4. Nikolis A, et al. A comprehensive interim analysis of skin hydration, barrier\nfunction (TEWL), elasticity, and patient satisfaction across two treatment\narms. Interim Data on File. April 2026.\n\n 5. Nikolis A, et al. Evaluating the role of small particle hyaluronic acid\nfillers using micro-droplet technique in the face, neck and hands: a\nretrospective chart review. Clin Cosmet Investig Dermatol. 2018;11:467–475.\ndoi: 10.2147/CCID.S175408.\n\n 6. Humphrey CD & Lawrence AC. Implications of Ozempic and other GLP-1\nreceptor agonists for facial plastic surgeons. Facial Plast Surg.\n2023;39:719-72.\n\n 7. Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol\nSurg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.\n\n 8. Belmontesi M, et al. Injectable non-animal stabilized hyaluronic acid as a\nskin quality booster: An expert panel consensus. J Drugs Dermatol.\n2018;17(1):83– 88.\n\n 9. Kim J. Effects of injection depth and volume of stabilized hyaluronic acid in\nhuman dermis on skin texture, hydration, and thickness. Arch Aesthet Plast\nSurg. 2014;20:97-103. doi:10.14730/aaps.2014.20.2.97.\n\n 10. Galderma. Data on file. MA-58650. Degree of modification of HA fillers.\n\n 11. Galderma. Data on file. Somenek M and Lorenc P. A multi-center, open-label\nstudy to evaluate the synergistic effects of biostimulator and dermal fillers\nfor cheek augmentation and correction of contour deficiencies: Nine-month\ntopline results.\n\n 12. Restylane(®) Shaype EU IFU.\n\n 13. Galderma. Data on file. U.S. FDA Restylane syringe PMA supplement approval\nletter.\n\n 14. Galderma. Data on file. Health Canada Restylane Medical Device License.\n\n 15. Galderma. Data on file. Dekra Restylane next generation syringe report.\n\n 16. Restylane(®) Contour™. US IFU.\n\n 17. Galderma. Data on file. MA-63365 Study Report. 2025.\n\n 18. Galderma. Data on file. Restylane Contour temple investigator closeout meeting\nexecutive summary. 2025.\n\n 19. Park KE, et al. Response of 21 hyaluronic acid fillers to recombinant human\nhyaluronidase. Plast Reconstr Surg Glob Open. 2023;11:e5457.\ndoi:10.1097/GOX.0000000000005457.\n\n 20. Verpaele A, Strand A. Restylane SubQ, a non-animal stabilized hyaluronic acid\ngel for soft tissue augmentation of the mid-and lower face. Aesthetic Surg J.\n2006;26(Suppl.):S10–17. doi: 10.1016/j.asj.2005.09.009.\n\n 21. Nikolis A, et al. Effectiveness and safety of a new hyaluronic acid injectable\nfor augmentation and correction of chin retrusion. J Drugs Dermatol.\n2024;23(4):255–61. doi: 10.36849/JDD.8145.\n\n 22. Öhrlund Å, et al. Differentiation of NASHA and OBT hyaluronic acid gels\naccording to strength, flexibility, and associated clinical significance. J\nDrugs Dermatol. 2024;23(1):1332–6. doi: 10.36849/JDD.7648.\n\n 23. Restylane(®) Lyft™. EU IFU.\n\n 24. Restylane(®) Classic. EU IFU.\n\n 25. Restylane(®) Eyelight™. EU IFU.\n\n 26. Restylane(®) Defyne™. EU IFU.\n\n 27. Restylane(®) Volyme™. EU IFU.\n\n 28. Restylane(®) Kysse™. EU IFU.\n\n 29. Restylane(®) Refyne™. EU IFU.\n\n 30. Restylane(®) Skinboosters Vital Lidocane™. EU IFU.\n\n 31. Restylane(®) Skinboosters Vital Light Lidocane™. EU IFU.\n\n 32. European Medicines Agency. Available \nonline\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fabout-us%2Fwhat-we-do%23more-on-what-ema-does-12354&esheet=54616526&newsitemid=20261005211995&lan=en-US&anchor=online&index=4&md5=faf3f5ca3c4219ba4ff419f70b61eab5)\n\n. Accessed October 2026.\n\n 33. Galderma. Data on file. MA-56724. 2023. Global rheology data (xStrain and G´\nincluding Restylane SHAYPE).\n\n 34. Galderma. Data on file. MA-64737.\n\n 35. Galderma. Data on file. MA-56005.\n\n 36. Galderma. Data on file. Design and development of the next generation syringe.\n\n 37. Galderma. Data on file. MA-59168.\n\n 38. Galderma. Data on file. Vimer S.r.l. Declaration of recycling compliance.\n2025.\n\n 39. Galderma. Data on file. MA-63907.\n\n 40. Galderma. Data on file. Restylane next generation syringe HCP survey.\n\n 41. Landau M, Fagien S. Science of Hyaluronic Acid Beyond Filling: Fibroblasts and\nTheir Response to the Extracellular Matrix. Plast Reconstr Surg.\n2015;136(5S):188S–195S. doi: 10.1097/PRS.0000000000001823.\n\n 42. Qin J. Ozempic face: A new challenge for facial plastic surgeons. JPRAS.\n2023;81:97-98. doi: 10.1016/j.bjps.2023.04.057.\n\n 43. Galderma. Data on File. MA-60875. A Single Center, Double-Blinded, Split-Body,\nRandomized Clinical Trial of Injectable Poly-L-Lactic Acid for Volumization\nand Adipogenesis of the Hip Dell.\n\n 44. Huth S, et al. Molecular Insights into the effects of PLLA-SCA on Gene\nExpression. J Drugs Dermatol. 2024;23(4):285-288. doi: 10.36849/JDD.7791.\n\n 45. Waibel J, et al. A randomized, comparative study describing the gene\nsignatures of poly-l-lactic acid (PLLA-SCA) and calcium hydroxylapaptite\n(CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS 2024,\nFebruary 1-3, 2024, Paris, France.\n\n 46. Sculptra(®). EU Instructions for Use. 2025. Available \nonline\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.galderma.com%2Fsites%2Fdefault%2Ffiles%2F2025-12%2FIFU_Sculptra_MDR.pdf&esheet=54616526&newsitemid=20261005211995&lan=en-US&anchor=online&index=5&md5=4e6088d35ca469934102d2e387afdd1d)\n\n. Accessed October 2026.\n\n 47. Haddad A, et al. International consensus: Sculptra(®)/Restylane(®)\nSkinboosters™ for non-facial rejuvenation. Poster presented at IMCAS 2026;\nJanuary 29-31, 2026; Paris, France.\n\n 48. Galderma. Data on file. MA-48544 Subject satisfaction (GAIS) – NASHA and OBT\nFillers. 2021.\n\n 49. Kablik J, et al. Comparative physical properties of HA dermal fillers.\nDermatol Surg. 2009; 35, 302–312. doi: 10.1111/j.1524-4725.2008.01046.x.\n\n 50. Solish N, et al. Dynamics of HA fillers formulated to maintain natural facial\nexpression. J Cosmet Dermatol. 2019;18(3):738-746. doi: 10.1111/jocd.12961.\n\n 51. Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after\nHA filler injection in nasolabial folds and lower face. J Cosmet Dermatol.\n2020;19(7):1600-1606. doi: 10.1111/jocd.1320.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261005211995/en/\n(https://www.businesswire.com/news/home/20261005211995/en/)\n\nFor further information:\n\n\n\nChristian Marcoux, M.Sc.\n\nChief Communications Officer\n\nchristian.marcoux@galderma.com \n(mailto:christian.marcoux@galderma.com) \n+41 76 315 26 50\n\n\n\nRichard Harbinson\n\nCorporate Communications Director\n\nrichard.harbinson@galderma.com \n(mailto:richard.harbinson@galderma.com) \n+41 76 210 60 62\n\n\n\nCéline Buguet\n\nFranchises and R&D Communications Director\n\nceline.buguet@galderma.com \n(mailto:celine.buguet@galderma.com) \n+41 76 249 90 87\n\n\n\nEmil Ivanov\n\nHead of Strategy, Investor Relations, and ESG\n\nemil.ivanov@galderma.com \n(mailto:emil.ivanov@galderma.com) \n+41 21 642 78 12\n\n\n\nJessica Cohen\n\nInvestor Relations and Strategy Director\n\njessica.cohen@galderma.com \n(mailto:jessica.cohen@galderma.com) \n+41 21 642 76 43\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw3BP9rda-20261006","title":"30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation ","author":"Business Wire","ticker":"GALD","created":"2026-10-06T05:00:00.191Z","tickers":["GALD"],"exchange":"","article_body":"30 Years of Restylane(®): Reshaping the Aesthetics Field Through Science-Led,\nPatient-Centric Innovation\n\n\n * Galderma celebrates the 30(th) anniversary of Restylane, its pioneering range\nof hyaluronic acid (HA) injectables that established the category as the first\nto market(1 )\n\n * With three decades of innovation across technology, packaging, and treatment\nareas, Restylane continues to meet growing aesthetic needs, including emerging\nareas such as medication-driven weight loss, skin quality and menopause(1-11)\n\n * This year’s milestones include the approvals of Restylane Shaype™ in the\nEuropean Union (EU) for enhancement of the chin region, the new\nstate-of-the-art Restylane syringe in the EU, United States (U.S.), and\nCanada, and Restylane Volyme™* in the U.S. for temple hollowing, with a\ndual-layer patent-pending technique leveraging both needle and cannula(12-18)\n\n * With more than 80 clinical trials, 180 publications, around 407,000 patients\nevaluated for safety, and 77 million treatments administered worldwide,\nRestylane remains a pioneer in science-backed aesthetic innovation and\ncontinues to shape the future of HA injectables(1-3,19,20)\n\nGalderma (SIX: GALD), the pure-play dermatology category leader, celebrates 30\nyears since Restylane was launched in Europe as the first hyaluronic acid (HA)\ninjectable.(1 )With HA closest to the skin’s own, Restylane is designed to\ndeliver personalized, natural-looking outcomes that meet diverse patient needs\nacross key areas of the face, décolletage, and hands.(8,10,12,21-31) With\nthree decades of innovation across technology, packaging, and treatment areas,\nRestylane remains at the forefront of innovation, evolving from its original\nNASHA(®), technology into a comprehensive portfolio spanning three distinct\ntechnologies: NASHA HD™, NASHA(®), and OBT™.(1,8,21,22 )Together, these\ntechnologies offer solutions ranging from firmer gels that provide contouring\nand structural support, to soft, flexible formulations that smooth facial\nlines and wrinkles for a more youthful look.(8,12,21-31)\n\nThis press release features multimedia. View the full release here:\nhttps://www.businesswire.com/news/home/20261005211995/en/\n(https://www.businesswire.com/news/home/20261005211995/en/)\n\nThe Restylane portfolio has most recently achieved EU Medical Device\nRegulation certification for the products created with NASHA HD™, NASHA(®),\nand OBT™ technologies.(12,23-29) As one of the world's most rigorous medical\ndevice regulatory frameworks, the certification reinforces confidence in the\nstrong safety profile, quality standards and scientific foundation behind the\nportfolio.(32)\n                                                                                      \n  “Restylane's 30-year journey is a testament to Galderma's enduring                  \n commitment to science-led innovation in aesthetics. Supported by extensive           \n clinical experience – including more than 400,000 patients evaluated for             \n safety – and robust real-world data, Restylane has helped define aesthetics,         \n setting a high standard for safety, efficacy and natural-looking results since       \n it launched as the first HA injectable three decades ago. With market                \n penetration still relatively low, significant opportunities remain to expand         \n adoption, and as we look to the future, we will continue to build on this            \n foundation through innovation that reinforces the essential role of HA               \n injectables in the future of aesthetics.”                                            \n \n                                                                                    \n \nBALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.                                           \n \nGLOBAL HEAD OF R&D                                                                  \n \nGALDERMA                                                                            \n                                                                                      \n\n\nExpanding Restylane’s versatility to support tailored aesthetic outcomes\n\nRestylane continues to expand treatment possibilities through new\ntechnologies, indications, and devices.\n\nRestylane Shaype was recently approved\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.galderma.com%2Fnews%2Fgalderma-receives-european-union-approval-restylaner-shaypetm-first-and-only-bone-mimicking&esheet=54616526&newsitemid=20261005211995&lan=en-US&anchor=approved&index=1&md5=d123a6254beb79d5ae7c48bc4aad7fd6)\nin the EU for correction and enhancement of the chin region.(12) Powered by\nGalderma’s new NASHA HD™ technology, it is the firmest HA injectable gel\navailable among facial filler market leaders, delivering a unique\nbone-mimicking effect that enables immediate, natural-looking structural\nenhancement in the lower face.(12,21,33) Restylane Shaype is the first\nminimally invasive injectable aesthetic option to provide structure in this\nincreasingly important treatment area, which has previously largely relied on\nsurgical implants.(21)\n\nA new state-of-the-art Restylane syringe was also approved in the EU, U.S. and\nCanada earlier this year, for use with the NASHA(®) lidocaine Restylane\nproducts in multiple facial indications.(13-15 )It was designed in\ncollaboration with over 70 aesthetics practitioners to be optimized for\nergonomic functionality, ease of aspiration, and ease of operation.(34-37) It\nhas compact blister-free packaging that is 100% recyclable and reduces\nin-clinic waste by up to 30% based on volume reduction.(38,39 )A survey of\nover 300 healthcare professionals in Brazil who had personal experience using\nthe Restylane syringes found that 89% preferred the next-generation syringe\nover the standard syringe.(40) The next-generation syringe complements\nGalderma’s patented SmartClick™ syringe for Restylane Skinboosters™,\nwhich monitors each micro-dose, allowing injectors to focus on technique and\nplacement for enhanced patient safety, precision and control.(31,41)\n\nAs global demand grows for treatments that address the evolving effects on the\nskin of aging, menopause, and weight loss, Restylane Volyme received U.S.\napproval in March for the correction of temple hollowing with a dual-layer\npatent-pending technique leveraging both needle and cannula.(16-18) Temple\nvolume loss can disrupt facial balance and harmony, and contribute to a tired,\nsunken, and aged appearance, a challenge increasingly seen in people\nundergoing medication-driven weight loss and experiencing age- and\nhormone-related changes, including menopause.(6,18,42)\n                                                                                      \n  “Restylane has been a trusted part of my practice for many years, thanks            \n to the constant innovations brought to the portfolio in terms of product,            \n indications and even packaging. Today, I treat an increasingly diverse range         \n of individuals seeking personalized, natural-looking results, so having a            \n versatile portfolio that goes beyond volumizing and can provide lift, contour,       \n definition and skin quality improvements across multiple areas of the face and       \n body is invaluable. Supported by decades of science, Restylane gives me the          \n confidence to tailor treatments to each patient’s unique anatomy, goals and          \n stage of life.”                                                                      \n \n                                                                                    \n \nDR. LUDDI LUIZ OLIVEIRA                                                             \n \nPLASTIC SURGEON                                                                     \n \nBRAZIL                                                                              \n                                                                                      \n\n\nRestylane expands access to injectable aesthetics for new patient segments\n\nRestylane remains highly relevant in addressing some of today’s most\nsignificant aesthetic trends and needs including medication-driven weight\nloss, menopause and skin quality.\n\nInterim results\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.galderma.com%2Fnews%2Finterim-data-two-ongoing-investigator-initiated-trials-highlight-role-sculptra-and-restylane&esheet=54616526&newsitemid=20261005211995&lan=en-US&anchor=results&index=2&md5=ddcf2456f74da3133ba5f503761cfef1)\nfrom an investigator-initiated trial showed that combining Restylane\nSkinboosters with Sculptra(®) – the first proven regenerative\nbiostimulator( )–( )drove progressive improvements in hydration, skin\nbarrier function, and overall skin quality in menopausal women.(4,43-46 )These\nresults are reinforced by consensus guidelines concluding that Restylane\nSkinboosters can complement Sculptra in the décolletage for comprehensive\nbody rejuvenation.(47)\n\nAdditionally, Restylane also has an important role in addressing the aesthetic\nconcerns of patients experiencing facial volume loss associated with\nmedication-driven weight loss.(11) The combination of Restylane Lyft™ or\nVolyme with Sculptra has been shown to deliver visible improvements in skin\nquality and significantly enhance patient satisfaction and emotional\nwellbeing.(11)\n\nSupported by 30 years of innovation and more than 77 million treatments\nadministered worldwide, Restylane has helped define the HA injectable category\nand continues to shape the future of aesthetic medicine.(1-3) With more than\n80 clinical trials, 180 publications and around 407,000 patients evaluated for\nsafety, its legacy is built on extensive scientific evidence and clinical\nexperience.(3,19) These milestones demonstrate Galderma’s ongoing commitment\nto using its unique dermatology expertise and strong portfolio to meet the\nneeds of patients and healthcare professionals today and tomorrow.\n\n*Restylane Volyme is known as Restylane Contour™ in the U.S.\n\nAbout the Restylane portfolio\n\nRestylane HA treatments are designed differently to go beyond volumizing for\nnatural-looking results.(2,24,48) Our HA is minimally modified and our\ninnovative manufacturing process preserves its biocompatibility while creating\nindividual products designed for a specific purpose.(7,10,49) Powered by NASHA\nHD™, NASHA(®), and OBT™ technologies, Restylane offers gels with the\nhighest firmness to the highest flexibility, enabling personalized treatments\nthat deliver structural support, natural-looking results, and a healthy\nglow.(8,21,22,33) Trusted for almost three decades, our HA gels work in sync\nwith your skin for 100% natural-looking results.(2,50,51) Approved indications\nvary by market.\n\nAbout Galderma\n\nGalderma (SIX: GALD) is the pure-play dermatology category leader, present in\napproximately 90 countries. We deliver an innovative, science-based portfolio\nof premium flagship brands and services that span the full spectrum of the\nfast-growing dermatology market through Injectable Aesthetics, Dermatological\nSkincare and Therapeutic Dermatology. Since our foundation in 1981, we have\ndedicated our focus and passion to the human body’s largest organ – the\nskin – meeting individual consumer and patient needs with superior outcomes\nin partnership with healthcare professionals. Because we understand that the\nskin we are in shapes our lives, we are advancing dermatology for every skin\nstory. For more information: www.galderma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.galderma.com%2F&esheet=54616526&newsitemid=20261005211995&lan=en-US&anchor=www.galderma.com&index=3&md5=fac463f7d2fcbee7a840240376e77c30)\n.\n\nReferences\n\n\n 1. Galderma. Data on file. MA-57232 [Updated]. 77 Million treated.\n\n 2. Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of\ninjectable HA fillers for facial aesthetic treatment. E-poster presented at\nAMWC; March 27-29, 2024; Monaco.\n\n 3. Galderma. Data on file. MA-55607. Restylane(®) 27 years data publications\nanalysis.\n\n 4. Nikolis A, et al. A comprehensive interim analysis of skin hydration, barrier\nfunction (TEWL), elasticity, and patient satisfaction across two treatment\narms. Interim Data on File. April 2026.\n\n 5. Nikolis A, et al. Evaluating the role of small particle hyaluronic acid\nfillers using micro-droplet technique in the face, neck and hands: a\nretrospective chart review. Clin Cosmet Investig Dermatol. 2018;11:467–475.\ndoi: 10.2147/CCID.S175408.\n\n 6. Humphrey CD & Lawrence AC. Implications of Ozempic and other GLP-1\nreceptor agonists for facial plastic surgeons. Facial Plast Surg.\n2023;39:719-72.\n\n 7. Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol\nSurg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.\n\n 8. Belmontesi M, et al. Injectable non-animal stabilized hyaluronic acid as a\nskin quality booster: An expert panel consensus. J Drugs Dermatol.\n2018;17(1):83– 88.\n\n 9. Kim J. Effects of injection depth and volume of stabilized hyaluronic acid in\nhuman dermis on skin texture, hydration, and thickness. Arch Aesthet Plast\nSurg. 2014;20:97-103. doi:10.14730/aaps.2014.20.2.97.\n\n 10. Galderma. Data on file. MA-58650. Degree of modification of HA fillers.\n\n 11. Galderma. Data on file. Somenek M and Lorenc P. A multi-center, open-label\nstudy to evaluate the synergistic effects of biostimulator and dermal fillers\nfor cheek augmentation and correction of contour deficiencies: Nine-month\ntopline results.\n\n 12. Restylane(®) Shaype EU IFU.\n\n 13. Galderma. Data on file. U.S. FDA Restylane syringe PMA supplement approval\nletter.\n\n 14. Galderma. Data on file. Health Canada Restylane Medical Device License.\n\n 15. Galderma. Data on file. Dekra Restylane next generation syringe report.\n\n 16. Restylane(®) Contour™. US IFU.\n\n 17. Galderma. Data on file. MA-63365 Study Report. 2025.\n\n 18. Galderma. Data on file. Restylane Contour temple investigator closeout meeting\nexecutive summary. 2025.\n\n 19. Park KE, et al. Response of 21 hyaluronic acid fillers to recombinant human\nhyaluronidase. Plast Reconstr Surg Glob Open. 2023;11:e5457.\ndoi:10.1097/GOX.0000000000005457.\n\n 20. Verpaele A, Strand A. Restylane SubQ, a non-animal stabilized hyaluronic acid\ngel for soft tissue augmentation of the mid-and lower face. Aesthetic Surg J.\n2006;26(Suppl.):S10–17. doi: 10.1016/j.asj.2005.09.009.\n\n 21. Nikolis A, et al. Effectiveness and safety of a new hyaluronic acid injectable\nfor augmentation and correction of chin retrusion. J Drugs Dermatol.\n2024;23(4):255–61. doi: 10.36849/JDD.8145.\n\n 22. Öhrlund Å, et al. Differentiation of NASHA and OBT hyaluronic acid gels\naccording to strength, flexibility, and associated clinical significance. J\nDrugs Dermatol. 2024;23(1):1332–6. doi: 10.36849/JDD.7648.\n\n 23. Restylane(®) Lyft™. EU IFU.\n\n 24. Restylane(®) Classic. EU IFU.\n\n 25. Restylane(®) Eyelight™. EU IFU.\n\n 26. Restylane(®) Defyne™. EU IFU.\n\n 27. Restylane(®) Volyme™. EU IFU.\n\n 28. Restylane(®) Kysse™. EU IFU.\n\n 29. Restylane(®) Refyne™. EU IFU.\n\n 30. Restylane(®) Skinboosters Vital Lidocane™. EU IFU.\n\n 31. Restylane(®) Skinboosters Vital Light Lidocane™. EU IFU.\n\n 32. European Medicines Agency. Available \nonline\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fabout-us%2Fwhat-we-do%23more-on-what-ema-does-12354&esheet=54616526&newsitemid=20261005211995&lan=en-US&anchor=online&index=4&md5=faf3f5ca3c4219ba4ff419f70b61eab5)\n\n. Accessed October 2026.\n\n 33. Galderma. Data on file. MA-56724. 2023. Global rheology data (xStrain and G´\nincluding Restylane SHAYPE).\n\n 34. Galderma. Data on file. MA-64737.\n\n 35. Galderma. Data on file. MA-56005.\n\n 36. Galderma. Data on file. Design and development of the next generation syringe.\n\n 37. Galderma. Data on file. MA-59168.\n\n 38. Galderma. Data on file. Vimer S.r.l. Declaration of recycling compliance.\n2025.\n\n 39. Galderma. Data on file. MA-63907.\n\n 40. Galderma. Data on file. Restylane next generation syringe HCP survey.\n\n 41. Landau M, Fagien S. Science of Hyaluronic Acid Beyond Filling: Fibroblasts and\nTheir Response to the Extracellular Matrix. Plast Reconstr Surg.\n2015;136(5S):188S–195S. doi: 10.1097/PRS.0000000000001823.\n\n 42. Qin J. Ozempic face: A new challenge for facial plastic surgeons. JPRAS.\n2023;81:97-98. doi: 10.1016/j.bjps.2023.04.057.\n\n 43. Galderma. Data on File. MA-60875. A Single Center, Double-Blinded, Split-Body,\nRandomized Clinical Trial of Injectable Poly-L-Lactic Acid for Volumization\nand Adipogenesis of the Hip Dell.\n\n 44. Huth S, et al. Molecular Insights into the effects of PLLA-SCA on Gene\nExpression. J Drugs Dermatol. 2024;23(4):285-288. doi: 10.36849/JDD.7791.\n\n 45. Waibel J, et al. A randomized, comparative study describing the gene\nsignatures of poly-l-lactic acid (PLLA-SCA) and calcium hydroxylapaptite\n(CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS 2024,\nFebruary 1-3, 2024, Paris, France.\n\n 46. Sculptra(®). EU Instructions for Use. 2025. Available \nonline\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.galderma.com%2Fsites%2Fdefault%2Ffiles%2F2025-12%2FIFU_Sculptra_MDR.pdf&esheet=54616526&newsitemid=20261005211995&lan=en-US&anchor=online&index=5&md5=4e6088d35ca469934102d2e387afdd1d)\n\n. Accessed October 2026.\n\n 47. Haddad A, et al. International consensus: Sculptra(®)/Restylane(®)\nSkinboosters™ for non-facial rejuvenation. Poster presented at IMCAS 2026;\nJanuary 29-31, 2026; Paris, France.\n\n 48. Galderma. Data on file. MA-48544 Subject satisfaction (GAIS) – NASHA and OBT\nFillers. 2021.\n\n 49. Kablik J, et al. Comparative physical properties of HA dermal fillers.\nDermatol Surg. 2009; 35, 302–312. doi: 10.1111/j.1524-4725.2008.01046.x.\n\n 50. Solish N, et al. Dynamics of HA fillers formulated to maintain natural facial\nexpression. J Cosmet Dermatol. 2019;18(3):738-746. doi: 10.1111/jocd.12961.\n\n 51. Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after\nHA filler injection in nasolabial folds and lower face. J Cosmet Dermatol.\n2020;19(7):1600-1606. doi: 10.1111/jocd.1320.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261005211995/en/\n(https://www.businesswire.com/news/home/20261005211995/en/)\n\nFor further information:\n\n\n\nChristian Marcoux, M.Sc.\n\nChief Communications Officer\n\nchristian.marcoux@galderma.com \n(mailto:christian.marcoux@galderma.com) \n+41 76 315 26 50\n\n\n\nRichard Harbinson\n\nCorporate Communications Director\n\nrichard.harbinson@galderma.com \n(mailto:richard.harbinson@galderma.com) \n+41 76 210 60 62\n\n\n\nCéline Buguet\n\nFranchises and R&D Communications Director\n\nceline.buguet@galderma.com \n(mailto:celine.buguet@galderma.com) \n+41 76 249 90 87\n\n\n\nEmil Ivanov\n\nHead of Strategy, Investor Relations, and ESG\n\nemil.ivanov@galderma.com \n(mailto:emil.ivanov@galderma.com) \n+41 21 642 78 12\n\n\n\nJessica Cohen\n\nInvestor Relations and Strategy Director\n\njessica.cohen@galderma.com \n(mailto:jessica.cohen@galderma.com) \n+41 21 642 76 43\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-06T05:00:00.247467678Z","server_sent_at_ms":1791262800247},"received_at":"2026-10-06T05:00:00.380Z","source_url":"https://www.businesswire.com/news/home/20261005211995/en/"},"analysis":{"id":"149728","press_release_id":"161186","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Galderma is marking 30 years since Restylane launched as the first hyaluronic acid injectable, with 77 million treatments administered worldwide and roughly 407,000 patients evaluated for safety.\n\n2026 milestones include EU approval of Restylane Shaype for chin enhancement, U.S. approval of Restylane Volyme for temple hollowing, and a next-generation syringe approved in the EU, U.S., and Canada that cuts in-clinic packaging waste by up to 30%.\n\nThe release highlights growth drivers tied to medication-driven weight loss, menopause, and skin quality, positioning Restylane against low current market penetration — a brand-franchise story rather than new financial disclosure.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Restylane at 30: Galderma leans on GLP-1-era volume loss demand and new indications to expand HA injectable adoption."},"keyFigures":{"customDimensions":{"publications":180,"clinical_trials":"more than 80","countries_present":"approximately 90","hcp_syringe_preference":"89% of 300+ Brazilian HCPs","packaging_waste_reduction":"up to 30%","patients_evaluated_for_safety":"around 407,000","treatments_administered_worldwide":"77 million"}},"quotedText":"With market penetration still relatively low, significant opportunities remain to expand adoption","namedEntities":{"people":[{"name":"Baldio Scassellati Sforzolini","role":"Global Head of R&D, Galderma"},{"name":"Dr. Luddi Luiz Oliveira","role":"Plastic Surgeon, Brazil"},{"name":"Christian Marcoux","role":"Chief Communications Officer"},{"name":"Emil Ivanov","role":"Head of Strategy, Investor Relations, and ESG"}],"products":["Restylane","Restylane Shaype","Restylane Volyme","Restylane Contour","Restylane Skinboosters","Restylane Lyft","Sculptra","SmartClick syringe","NASHA HD","NASHA","OBT"],"companies":[{"name":"Galderma","ticker":"GALD","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Milestone/branding anniversary release with recent product approvals recapped (Restylane Shaype EU, Volyme US temple indication, new syringe). No new financials, approvals, or trials; incremental brand reinforcement for Galderma's injectable aesthetics franchise."},"tickerRelevance":{"others":[],"primary":"GALD"},"globalImportance":20,"audienceRelevance":30,"eventTypeSecondary":["product_launch"],"importanceComponents":{"tickerTier":"large-cap Swiss-listed specialty dermatology","eventGravity":"brand anniversary / product milestone recap, no new approvals or financials","issuerAuthored":true,"householdBrandBoost":"Restylane is a well-known aesthetics consumer-facing brand"}},"event_type":"operations_update","event_type_secondary":["product_launch"],"sentiment":"bullish","material_impact_score":2,"narrative":"Galderma is marking 30 years since Restylane launched as the first hyaluronic acid injectable, with 77 million treatments administered worldwide and roughly 407,000 patients evaluated for safety.\n\n2026 milestones include EU approval of Restylane Shaype for chin enhancement, U.S. approval of Restylane Volyme for temple hollowing, and a next-generation syringe approved in the EU, U.S., and Canada that cuts in-clinic packaging waste by up to 30%.\n\nThe release highlights growth drivers tied to medication-driven weight loss, menopause, and skin quality, positioning Restylane against low current market penetration — a brand-franchise story rather than new financial disclosure.","key_figures":{"customDimensions":{"publications":180,"clinical_trials":"more than 80","countries_present":"approximately 90","hcp_syringe_preference":"89% of 300+ Brazilian HCPs","packaging_waste_reduction":"up to 30%","patients_evaluated_for_safety":"around 407,000","treatments_administered_worldwide":"77 million"}},"named_entities":{"people":[{"name":"Baldio Scassellati Sforzolini","role":"Global Head of R&D, Galderma"},{"name":"Dr. Luddi Luiz Oliveira","role":"Plastic Surgeon, Brazil"},{"name":"Christian Marcoux","role":"Chief Communications Officer"},{"name":"Emil Ivanov","role":"Head of Strategy, Investor Relations, and ESG"}],"products":["Restylane","Restylane Shaype","Restylane Volyme","Restylane Contour","Restylane Skinboosters","Restylane Lyft","Sculptra","SmartClick syringe","NASHA HD","NASHA","OBT"],"companies":[{"name":"Galderma","ticker":"GALD","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-06T05:00:06.629Z","global_importance":20,"audience_relevance":30,"importance_components":{"tickerTier":"large-cap Swiss-listed specialty dermatology","eventGravity":"brand anniversary / product milestone recap, no new approvals or financials","issuerAuthored":true,"householdBrandBoost":"Restylane is a well-known aesthetics consumer-facing brand"}},"durationMs":6234,"modelName":"glm-5.3-flashx"}}